Bloomberg Anywhere Remote Login Bloomberg Terminal Request a Demo

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us

Genmab Plunges as Investor Sells 5.5% Stake: Copenhagen Mover

June 11 (Bloomberg) -- Genmab A/S, the Danish company developing cancer drugs, fell the most in 14 months in Copenhagen trading after an investor offered to sell a 5.5 percent stake at a price below yesterday’s close.

Genmab dropped as much as 14 percent, the most since April 2012. The stock declined 11 percent to 194.90 kroner at 12:26 p.m. in the Danish capital, with trading volume at 377 percent of the three-month daily average.

Genmab shares have jumped more than 150 percent this year as investors bet Arzerra, a treatment developed with GlaxoSmithKline Plc and daratumumab, a drug made with Johnson & Johnson, will boost profits at the Copenhagen-based company. Morgan Stanley is arranging a sale of 2.8 million Genmab shares for an unidentified investor, offering the stock at 200 kroner to 205 kroner a piece, according to term sheets obtained by Bloomberg News.

Meditor Capital Management Ltd. has sold its entire stake in the Danish company, Genmab said today in a regulatory filing. Genmab said in September 2010 that Meditor had bought a 5.69 percent stake.

Analysts have in the past year more than doubled their price estimates on the Genmab share, according to data compiled by Bloomberg. The average 12-month target rose to 200.50 kroner this week, the highest since August 2009.

To contact the reporters on this story: Francesca Cinelli in Milan at fcinelli@bloomberg.net; Gaurav Panchal in London at gpanchal2@bloomberg.net

To contact the editor responsible for this story: James Ludden at jludden@bloomberg.net

Please upgrade your Browser

Your browser is out-of-date. Please download one of these excellent browsers:

Chrome, Firefox, Safari, Opera or Internet Explorer.